1. SWAG SSG Lung Cancer Meeting
Clinical Research Network
West of England
SWAG SSG Lung Cancer Meeting
Tuesday 15th November 2016
Research Report

2. Clinical Research Network & Cancer Services
West ofEngland
SWAG - Somerset Wiltsire Avon & Gloucestershire
South West Children’s Cancer & Leukaemia
Research Network

3. NIHR CRN – what does it do?
Infrastructure that allows high-quality clinical research to take place in the NHS
Help researchers to set up clinical studies quickly and effectively
Support the life-sciences industry to deliver their research programmes in the NHS
Provide health professionals with research training
Work with patients to ensure their needs are at the very centre of all research activity.

4. NIHR CRN High Level Objectives
Increase number of participants into NIHR CRN portfolio studies
650,000 in England
21,905 in West of England
Increase the number of studies that deliver to time and target
Target 80%
Increase number of commercial studies delivered through network
650 new studies this year
75% of all commercial studies
Reduce NHS study set up times
Reduce time taken to recruit first participant

5. Local Clinical Research Networks
Translation of national objectives for clinical research
Oversight of research activity within the geography of CRN - West of England in terms of:
Portfolio
Balance, new studies, feasibility, set up, industry trials
Performance
Support, network wide solutions, targets
People
Patient involvement, staff skill mix & flexibility, training, resources

6. 30 Clinical Specialties Ageing Anaesthetics & pain Cancer
Cardiovascular
Children
Critical Care
Dementia & Neurodegenerative
Dermatology
Diabetes
ENT
Gastroenterology
Genetics
Haematology
Health Services
Hepatology
Infectious Diseases
Injuries & Emergencies
Mental Health
Metabolic & Endocrine
Musculoskeletal
Neurological
Opthalmology
Oral & Dental
Primary Care
Public Health
Renal
Reproductive Health
Respiratory
Stroke
Surgery

7. Including lymphoma

8. Local CRN sub specialty leads
NCRI Clinical Studies Groups
NIHR CRN cancer leadership

9. National Clinical Studies Groups PPI Psychosocial & Survivorship
Imaging Adv. panel
Breast Cancer
CSG
Brain Tumours
CSG
Lung Cancer
CSG
Palliative & Supportive
Care
Head & Neck
CSG
Biomarkers Adv. panel
Upper GI Cancer
CSG
Consumer Liaison Group
Sarcoma
CSG
PPI
Colorectal Cancer
CSG
Melanoma
CSG
Kidney Cancer
CSG
Primary
Care
Lymphoma
CSG
Bladder Cancer
CSG
Screening, Prevention & Early Diagnosis
Haematol.
CSG
Testis Cancer
CSG
Prostate Cancer
CSG
Gynae Cancer
CSG
Children’s Cancer & Leukaemia
Teenage &
Young Adult
CTRad (Radiotherapy)

10. NIHR CRN Objectives for cancer
Recruit 20% of cancer incidence
West of England 1,909
Recruit 7.5% of cancer incidence into interventional studies
716
Include challenging studies
Cancer surgery – 4 recruits per 100,000 population
Radiotherapy – 6 recruits per 100,000 population
Rare cancers (<6 per 100,000) – 12 recruits per 100,000 population
Children & young people – 3 per 100,000 population
Teenagers & young adults – record number of year olds participating in research

14. Open studies in SWAG – Lung Cancer portfolio
BRAG
Open studies
Black
Study not reported recruitment or study has not recruited
Red
% Recruitment is more than 30 behind % time elapsed, i.e. Difference < -30
Amber
% Recruitment is less than 30 behind % elapsed time but more than 0 behind % elapsed time, i.e. -30 < Difference < 0
Green
% Recruitment is equal to or greater than % elapsed time, i.e. Difference >= 0
Grey
Unable to calculate RAG due to record missing at least one data point

15. Open studies in SWAG – Lung Cancer portfolio

16. Studies in set up – Lung Cancer

17. Commercial studies with outstanding expressions of interest

18. JAVELIN open at Cheltenham. PI David Farrugia
This trial give patients access to new immunotherapy (PD-1 Inhibitors) as first line treatment (currently only available to a sub population of patients with Pembrolizumab on EAMS provided they score at least 50% positivity on tumour testing). The EAMS programme will close as soon as the drug gets a licence.  
This trial also allows crossover to the IMP on progression in the control arm.  This makes PD-L1 inhibitors as second line therapy available to our patients (rejected by NICE recently so no idea when this will be available on the NHS.)
We are looking for motivated patients with PS0-1 who are willing to travel (expenses covered).

19. Useful links https://www.crn.nihr.ac.uk/
National and local network information including training programmes templates, tools, contacts, videos etc
Open data platform. Look at performance across whole CRN including all specialty areas
/csg.ncri.org.uk/portfolio/portfolio-maps/
View current national portfolio of open, closed and ‘in set up’ cancer studies
See where a study is open across the country
Search for a study to fit criteria. Good for horizon scanning, eligibility criteria

20. Contacts Research Delivery Manager – maxine.taylor@nihr.ac.uk
Cancer portfolio facilitator –